California Public Employees Retirement System boosted its holdings in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 23.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,200 shares of the company’s stock after buying an additional 3,300 shares during the period. California Public Employees Retirement System’s holdings in Crispr Therapeutics were worth $705,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of CRSP. NEXT Financial Group Inc lifted its position in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares in the last quarter. Benjamin Edwards Inc. increased its position in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new position in Crispr Therapeutics in the 3rd quarter worth about $26,000. US Bancorp DE raised its stake in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares in the last quarter. Finally, BSW Wealth Partners purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $39,000. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CRSP stock traded down $0.65 during mid-day trading on Wednesday, reaching $67.23. The stock had a trading volume of 371,420 shares, compared to its average volume of 1,043,579. Crispr Therapeutics AG has a one year low of $24.56 and a one year high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s 50 day simple moving average is $63.51 and its 200 day simple moving average is $50.09. The firm has a market cap of $3.71 billion, a PE ratio of -19.54 and a beta of 3.31.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Sell-side analysts forecast that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
Several equities research analysts recently commented on CRSP shares. Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of “Buy” and an average price target of $71.38.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last quarter. Corporate insiders own 21.40% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.